China, Sichuan
Chengdu, Sichuan, 611731, China
NCT Number: NCT02733237
To investigate whether intranasal oxytocin (40 IU) treatment can influence the tolerance of infidelity in males and females.
Looking for future studies?
Notify Me19 year–28 year
All sexes
Interventional
Not applicable
Chengdu, Sichuan, 611731, China
In a double-blind, between-subject, placebo controlled design, investigators plan to investigate the effect of oxytocin treatment on the tolerance of infidelity. Male and female subjects would firstly see a neutral face of the opposite sex presented with a sentence descried their fidelity or infidelity behavior (sexual or emotional) in a relationship. Next the participant will rate the attractiveness, likability and trustworthiness of each individual, and whether they would like to have a short/long relationship with him/her. After that there will be some implicit attitude tasks to test their implicit attitude towards potential partners exhibiting previous fidelity or and infidelity.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
intranasal administration of oxytocin (40 IU)
intranasal administration of placebo (40 IU)
Time frame: 1 hour
attitude is measured by the rating scores for likability, attractiveness and trustworthiness
University of Electronic Science and Technology of China
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details